"Parasympatholytics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.
| Descriptor ID |
D010276
|
| MeSH Number(s) |
D27.505.696.663.050.650
|
| Concept/Terms |
Parasympatholytics- Parasympatholytics
- Parasympatholytic Drugs
- Drugs, Parasympatholytic
- Parasympathetic-Blocking Agents
- Agents, Parasympathetic-Blocking
- Parasympathetic Blocking Agents
- Parasympatholytic Agents
- Agents, Parasympatholytic
Parasympatholytic Effect- Parasympatholytic Effect
- Effect, Parasympatholytic
- Parasympatholytic Effects
- Effects, Parasympatholytic
Antispasmodic Effect- Antispasmodic Effect
- Effect, Antispasmodic
- Antispasmodic Effects
- Effects, Antispasmodic
Antispasmodics- Antispasmodics
- Antispasmodic Drugs
- Drugs, Antispasmodic
- Spasmolytics
- Antispasmodic Agents
- Agents, Antispasmodic
|
Below are MeSH descriptors whose meaning is more general than "Parasympatholytics".
Below are MeSH descriptors whose meaning is more specific than "Parasympatholytics".
This graph shows the total number of publications written about "Parasympatholytics" by people in this website by year, and whether "Parasympatholytics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2000 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Parasympatholytics" by people in Profiles.
-
Maser RE, Lenhard MJ, Kolm P, Edwards DG. Direct renin inhibition improves parasympathetic function in diabetes. Diabetes Obes Metab. 2013 Jan; 15(1):28-34.
-
Davenport K, Timoney AG, Keeley FX. Effect of smooth muscle relaxant drugs on proximal human ureteric activity in vivo: a pilot study. Urol Res. 2007 Aug; 35(4):207-13.
-
Axelrod S, Bielory L. Beta2-agonists and paresthesias in multiple sclerosis. Ann Allergy Asthma Immunol. 2007 Jan; 98(1):100.
-
Brislin RP, Rose JB. Pediatric acute pain management. Anesthesiol Clin North Am. 2005 Dec; 23(4):789-814, x.
-
Borovikova LV, Ivanova S, Nardi D, Zhang M, Yang H, Ombrellino M, Tracey KJ. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci. 2000 Dec 20; 85(1-3):141-7.
-
Schneider H, Schaub CD, Chen CA, Andreoni KA, Schwartz AR, Smith PL, Robotham JL, O'Donnell CP. Effects of arousal and sleep state on systemic and pulmonary hemodynamics in obstructive apnea. J Appl Physiol (1985). 2000 Mar; 88(3):1084-92.
-
Shenot PJ, Chancellor MB, Rivas DA, Watanabe T, Kumon H, Figueroa TE. In-vivo whole bladder response to anticholinergic and musculotropic agents in spinal cord injured rats. J Spinal Cord Med. 1997 Jan; 20(1):31-5.
-
Rovner BW, David A, Lucas-Blaustein MJ, Conklin B, Filipp L, Tune L. Self-care capacity and anticholinergic drug levels in nursing home patients. Am J Psychiatry. 1988 Jan; 145(1):107-9.
-
Gollomp SM, Fahn S, Burke RE, Reches A, Ilson J. Therapeutic trials in Meige syndrome. Adv Neurol. 1983; 37:207-13.
-
SUROS J, BORDAS-FELIU JM, GOBERN J, SUROS-BATLLO J. [Therapeutic action of the new synthetic anticholinergic agent, benzylonium bromide, in diseases of the digestive tract]. Med Clin (Barc). 1963 Mar; 40:181-5.